To assess whether BRCA1/2 mutation has a differential impact on prognosis in breast cancer patients treated with neoadjuvant chemotherapy (NCT), while minimizing the effects of differences in treatment and clinicopathological characteristics, we utilized propensity score matching (PSM). This evidence concerns the gene BRCA1 and breast carcinoma.